switching to retatrutide from tirzepatide vs. Tirzepatide: What's The Difference? – Forbes Health 🚀 First Day on Retatrutide!

[15] [16] Current UK prescribing information (SmPCs) for licensed GLP-1 receptor agonists does not list a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2) as a contraindication, though individuals with such a history should discuss this with their clinician as a precautionary measure

Many researchers who transition from tirzepatide to retatrutide find the side effect timing quite similar since both medications share the GIP pathway

It is still investigational and legally available only through clinical trials

You need to identify and address issues before they occur to avoid costly losses

As of March 29, 2026 , retatrutide remains investigational , not FDA approved

Eli Lillys December 2025 press release reported average weight loss of up to 71.2 lbs at the highest dose, alongside substantial relief from osteoarthritis pain